Needham raised the firm’s price target on Glaukos (GKOS) to $176 from $149 and keeps a Buy rating on the shares after its Q4 results. The company’s iDose revenue grew sequentially to $16M and its 2025 guidance implies sales contribution of $115-120M, the analyst tells investors in a research note, adding that Glaukos is making further progress on its pipeline with Epioxa and Trio both expected to receive approval over the next 12-24 months.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GKOS:
- Glaukos price target raised to $160 from $153 at Wells Fargo
- Glaukos: Surpassing Milestones with Robust Growth in Glaucoma Segment and Promising iDose Integration
- Glaukos Corporation Reports Strong 2024 Financial Results
- Closing Bell Movers: Booking gains 3%, Akamai down 8% on earnings
- Glaukos down 14% at $135 after Q4 results and guidance